Advertisement
Singapore markets closed
  • Straits Times Index

    3,292.93
    -3.96 (-0.12%)
     
  • Nikkei

    38,236.07
    -37.98 (-0.10%)
     
  • Hang Seng

    18,475.92
    +268.79 (+1.48%)
     
  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     
  • Bitcoin USD

    63,616.13
    +1,885.63 (+3.05%)
     
  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • Dow

    38,675.68
    +450.02 (+1.18%)
     
  • Nasdaq

    16,156.33
    +315.37 (+1.99%)
     
  • Gold

    2,310.10
    +0.50 (+0.02%)
     
  • Crude Oil

    77.99
    -0.96 (-1.22%)
     
  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     
  • FTSE Bursa Malaysia

    1,589.59
    +9.29 (+0.59%)
     
  • Jakarta Composite Index

    7,134.72
    +17.30 (+0.24%)
     
  • PSE Index

    6,615.55
    -31.00 (-0.47%)
     

3 Reasons Wall Street Thinks InMode Can Rocket 47% Higher in 2023

3 Reasons Wall Street Thinks InMode Can Rocket 47% Higher in 2023

Individual investors who want help picking stocks have more than a few options to choose from, including the recommendations of Wall Street analysts. Right now, InMode (NASDAQ: INMD) is a medical technology stock that analysts on Wall Street can't seem to get enough of. Among those who follow InMode, the average analyst is targeting a 47% gain for the stock over the next year.